JPWO2019237065A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019237065A5 JPWO2019237065A5 JP2021518059A JP2021518059A JPWO2019237065A5 JP WO2019237065 A5 JPWO2019237065 A5 JP WO2019237065A5 JP 2021518059 A JP2021518059 A JP 2021518059A JP 2021518059 A JP2021518059 A JP 2021518059A JP WO2019237065 A5 JPWO2019237065 A5 JP WO2019237065A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- iodide
- subject
- injury
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 45
- 206010022114 Injury Diseases 0.000 claims description 34
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 24
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 230000004064 dysfunction Effects 0.000 claims description 10
- 210000001519 tissues Anatomy 0.000 claims description 8
- 200000000020 tissue injury Diseases 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 210000003205 Muscles Anatomy 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- 206010061920 Psychotic disease Diseases 0.000 claims description 6
- 230000001603 reducing Effects 0.000 claims description 6
- 150000002366 halogen compounds Chemical class 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000000451 tissue damage Effects 0.000 claims description 5
- 231100000827 tissue damage Toxicity 0.000 claims description 5
- 206010060945 Bacterial infection Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 206010057668 Cognitive disease Diseases 0.000 claims description 4
- 206010072076 Critical illness myopathy Diseases 0.000 claims description 4
- 206010066336 Critical illness polyneuropathy Diseases 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 210000003414 Extremities Anatomy 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 208000007882 Gastritis Diseases 0.000 claims description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M Lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 4
- 206010051606 Necrotising colitis Diseases 0.000 claims description 4
- 101700060139 OCT2 Proteins 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 210000002381 Plasma Anatomy 0.000 claims description 4
- 229940083599 Sodium Iodide Drugs 0.000 claims description 4
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 claims description 4
- 206010047461 Viral infection Diseases 0.000 claims description 4
- 208000001756 Virus Disease Diseases 0.000 claims description 4
- 230000000302 ischemic Effects 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- 230000017613 viral reproduction Effects 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 2
- 206010057666 Anxiety disease Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 230000036868 Blood Concentration Effects 0.000 claims description 2
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims description 2
- 229940046413 Calcium iodide Drugs 0.000 claims description 2
- 206010007554 Cardiac failure Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010070976 Craniocerebral injury Diseases 0.000 claims description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 2
- 206010019280 Heart failure Diseases 0.000 claims description 2
- 208000006443 Lactic Acidosis Diseases 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 claims description 2
- BLQJIBCZHWBKSL-UHFFFAOYSA-L Magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 claims description 2
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 2
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims description 2
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000004995 Necrotizing Enterocolitis Diseases 0.000 claims description 2
- 206010029151 Nephropathy Diseases 0.000 claims description 2
- 206010029315 Neuromuscular blockade Diseases 0.000 claims description 2
- 206010037759 Radiation injury Diseases 0.000 claims description 2
- 206010038428 Renal disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010039163 Right ventricular failure Diseases 0.000 claims description 2
- MSFPLIAKTHOCQP-UHFFFAOYSA-M Silver iodide Chemical compound I[Ag] MSFPLIAKTHOCQP-UHFFFAOYSA-M 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L Zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 claims description 2
- 230000001154 acute Effects 0.000 claims description 2
- 230000003078 antioxidant Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229910001640 calcium iodide Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 201000006233 congestive heart failure Diseases 0.000 claims description 2
- 230000001082 cryoprotectant Effects 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 230000003247 decreasing Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing Effects 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 201000009673 liver disease Diseases 0.000 claims description 2
- 229910001641 magnesium iodide Inorganic materials 0.000 claims description 2
- 230000003340 mental Effects 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 201000008839 post-traumatic stress disease Diseases 0.000 claims description 2
- 230000002335 preservative Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000306 recurrent Effects 0.000 claims description 2
- 239000003638 reducing agent Substances 0.000 claims description 2
- 201000010384 renal tubular acidosis Diseases 0.000 claims description 2
- 230000035812 respiration Effects 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 229940045105 silver iodide Drugs 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 230000002485 urinary Effects 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 230000002107 myocardial Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 210000004165 Myocardium Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682574P | 2018-06-08 | 2018-06-08 | |
| US62/682,574 | 2018-06-08 | ||
| US201862730927P | 2018-09-13 | 2018-09-13 | |
| US201862730945P | 2018-09-13 | 2018-09-13 | |
| US62/730,945 | 2018-09-13 | ||
| US62/730,927 | 2018-09-13 | ||
| PCT/US2019/036154 WO2019237065A1 (en) | 2018-06-08 | 2019-06-07 | Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527130A JP2021527130A (ja) | 2021-10-11 |
| JPWO2019237065A5 true JPWO2019237065A5 (es) | 2022-05-13 |
Family
ID=68770655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518059A Pending JP2021527130A (ja) | 2018-06-08 | 2019-06-07 | 組織傷害および集中治療後症候群の処置および予防のためのハロゲン化合物の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210252047A1 (es) |
| EP (1) | EP3801565A4 (es) |
| JP (1) | JP2021527130A (es) |
| KR (1) | KR20210018898A (es) |
| CN (1) | CN112469422A (es) |
| AU (1) | AU2019282820A1 (es) |
| CA (1) | CA3102792A1 (es) |
| IL (1) | IL279221A (es) |
| MX (1) | MX2020013306A (es) |
| WO (1) | WO2019237065A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3104939T (pt) | 2014-02-10 | 2024-07-17 | Fred Hutchinson Cancer Center | Tratamento de ataque cardíaco e lesão isquémica com iodeto de sódio |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248335B1 (en) * | 1997-10-29 | 2001-06-19 | Symbollon Corporation | Stabilized oral pharmaceutical composition containing iodide and iodate and method |
| CZ295765B6 (cs) * | 1998-07-29 | 2005-10-12 | Apa - Praha, S.R.O. | Léčebný přípravek s virucidním účinkem |
| GB0525504D0 (en) * | 2005-12-14 | 2006-01-25 | Bristol Myers Squibb Co | Antimicrobial composition |
| PT3104939T (pt) * | 2014-02-10 | 2024-07-17 | Fred Hutchinson Cancer Center | Tratamento de ataque cardíaco e lesão isquémica com iodeto de sódio |
-
2019
- 2019-06-07 WO PCT/US2019/036154 patent/WO2019237065A1/en unknown
- 2019-06-07 JP JP2021518059A patent/JP2021527130A/ja active Pending
- 2019-06-07 CA CA3102792A patent/CA3102792A1/en active Pending
- 2019-06-07 KR KR1020217000098A patent/KR20210018898A/ko unknown
- 2019-06-07 CN CN201980049776.3A patent/CN112469422A/zh active Pending
- 2019-06-07 MX MX2020013306A patent/MX2020013306A/es unknown
- 2019-06-07 AU AU2019282820A patent/AU2019282820A1/en active Pending
- 2019-06-07 EP EP19814153.3A patent/EP3801565A4/en not_active Withdrawn
- 2019-06-07 US US16/972,718 patent/US20210252047A1/en not_active Abandoned
-
2020
- 2020-12-06 IL IL279221A patent/IL279221A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100252410B1 (ko) | 관상동맥수술후의 재협착의 치료 또는 예방을 위한 약학적 조성물 | |
| JP2014077003A5 (es) | ||
| JP2020529996A5 (es) | ||
| JP2019206562A5 (es) | ||
| JP2017533972A5 (es) | ||
| JP2020529440A5 (es) | ||
| JP2018507260A5 (es) | ||
| US20210283049A1 (en) | Intravenous sotalol hydrochloride loading and maintenance for cardiac surgery patients | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JPWO2019237065A5 (es) | ||
| JP2012533542A5 (es) | ||
| US20230241078A1 (en) | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | |
| JP2001089382A (ja) | 早期血管再生及び低分子量ヘパリン投与による不安定冠動脈疾患の治療方法 | |
| Kambam et al. | Histamine 2 receptor blocker in the treatment of protamine related anaphylactoid reactions: two case reports | |
| JP2019535830A5 (es) | ||
| TW200409643A (en) | Preventive agents for diabetes mellitus | |
| JP2018537522A (ja) | 組合せ | |
| AU2016364380B2 (en) | Formulations for intravenous injection of danirixin | |
| JP2020100601A (ja) | 一酸化窒素合成酵素活性化剤 | |
| Frenkel et al. | Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy-Case Report | |
| Clifford et al. | Intensive nitrogen mustard therapy with abdominal aortic occlusion in nasopharyngeal carcinoma | |
| JP2021091608A5 (es) | ||
| JP2019521184A5 (es) | ||
| Flaherty et al. | M31 Safety of combined pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis | |
| JP2019504085A5 (es) |